Terms: = Skin cancer AND CARS, P49589, 833, ENSG00000110619 AND Treatment
32 results:
1. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract] [Full Text] [Related]
2. Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract] [Full Text] [Related]
3. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
Zijlker LP; Levy S; Wolters W; van Thienen JV; van Akkooi ACJ; Tesselaar MET
Cancer; 2024 Feb; 130(3):433-438. PubMed ID: 37788133
[TBL] [Abstract] [Full Text] [Related]
4. Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations.
Zhang L; Cao L; Li S; Wang L; Song Y; Huang Y; Xu Z; He J; Wang M; Li K
J Immunother; 2023 Jul-Aug 01; 46(6):221-231. PubMed ID: 37220017
[TBL] [Abstract] [Full Text] [Related]
5. skin cancer incidence in transgender individuals receiving gender-affirming hormone treatment: a nationwide cohort study in the Netherlands.
Rahmat A; De Nie I; Wiepjes CM; Den Heijer M; Rustemeyer T; De Blok CJM; Dreijerink KMA
Int J Dermatol; 2023 Jul; 62(7):882-887. PubMed ID: 37140088
[TBL] [Abstract] [Full Text] [Related]
6. Artificial Intelligence and Advanced Melanoma: treatment Management Implications.
Guerrisi A; Falcone I; Valenti F; Rao M; Gallo E; Ungania S; Maccallini MT; Fanciulli M; Frascione P; Morrone A; Caterino M
Cells; 2022 Dec; 11(24):. PubMed ID: 36552729
[TBL] [Abstract] [Full Text] [Related]
7. COVID-19 related decline in cancer screenings most pronounced for elderly patients and women in Germany: a claims data analysis.
Muschol J; Strauss C; Gissel C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5345-5367. PubMed ID: 36436091
[TBL] [Abstract] [Full Text] [Related]
8. Anticancer traits of chimeric antigen receptors (cars)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber JS; Schadendorf D; Del Vecchio M; Larkin J; Atkinson V; Schenker M; Pigozzo J; Gogas H; Dalle S; Meyer N; Ascierto PA; Sandhu S; Eigentler T; Gutzmer R; Hassel JC; Robert C; Carlino MS; Di Giacomo AM; Butler MO; Muñoz-Couselo E; Brown MP; Rutkowski P; Haydon A; Grob JJ; Schachter J; Queirolo P; de la Cruz-Merino L; van der Westhuizen A; Menzies AM; Re S; Bas T; de Pril V; Braverman J; Tenney DJ; Tang H; Long GV
J Clin Oncol; 2023 Jan; 41(3):517-527. PubMed ID: 36162037
[TBL] [Abstract] [Full Text] [Related]
10. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
To V; Evtimov VJ; Jenkin G; Pupovac A; Trounson AO; Boyd RL
Front Immunol; 2022; 13():968395. PubMed ID: 36059451
[TBL] [Abstract] [Full Text] [Related]
11. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract] [Full Text] [Related]
12. Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs.
Augustin M; Girbig G; Kis A; Bechara FG; Hertl M; Hischke S; Kaufmann R; Löffler H; Müller CSL; Simon JC; Strömer K; Welzel J; Wetzig T; Elsner P; Augustin J; Löser C; Biedermann T
J Dtsch Dermatol Ges; 2021 Oct; 19 Suppl 5():25-53. PubMed ID: 34662491
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the treatment of Advanced Hepatocellular Carcinoma.
Li Z; Chen Q; Zhang W; Si G; Li J; Jiao D; Han X
Can J Gastroenterol Hepatol; 2021; 2021():5565793. PubMed ID: 34458205
[TBL] [Abstract] [Full Text] [Related]
14. High-Frequency Ultrasound for Evaluation of the Pathological Invasion Level of Extramammary Paget Disease.
Ma YY; Gong XH; Wang Q; Wang LF; Xu HX; Guo LH
J Ultrasound Med; 2022 Feb; 41(2):389-400. PubMed ID: 33856069
[TBL] [Abstract] [Full Text] [Related]
15. UV biomarker genes for classification and risk stratification of cutaneous actinic keratoses and squamous cell carcinoma subtypes.
Queen D; Shen Y; Trager MH; Lopez AT; Samie FH; Lewin JM; Niedt GW; Geskin LJ; Liu L
FASEB J; 2020 Sep; 34(9):13022-13032. PubMed ID: 32776588
[TBL] [Abstract] [Full Text] [Related]
16. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
Owen CN; Shoushtari AN; Chauhan D; Palmieri DJ; Lee B; Rohaan MW; Mangana J; Atkinson V; Zaman F; Young A; Hoeller C; Hersey P; Dummer R; Khattak MA; Millward M; Patel SP; Haydon A; Johnson DB; Lo S; Blank CU; Sandhu S; Carlino MS; Larkin JMG; Menzies AM; Long GV
Ann Oncol; 2020 Aug; 31(8):1075-1082. PubMed ID: 32387454
[TBL] [Abstract] [Full Text] [Related]
17. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract] [Full Text] [Related]
18. Think before you shave: Factors influencing choice of biopsy technique for invasive melanoma and effect on definitive management.
de Menezes SL; Wolfe R; Kelly JW; Farrugia H; Mar VJ
Australas J Dermatol; 2020 May; 61(2):134-139. PubMed ID: 31869446
[TBL] [Abstract] [Full Text] [Related]
19. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
[TBL] [Abstract] [Full Text] [Related]
20. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract] [Full Text] [Related]
[Next]
